23/06/2022 (Agence Europe) – The European Medicines Agency (EMA) recommended, on Thursday 23 June, an extension of the use of the vaccine developed by the firm Novavax CZ, a.s, called Nuvaxovid, in adolescents aged 12 to 17 years. The adjuvanted recombinant nanoparticle subunit vaccine was already licenced in the European Union for use in adults aged 18 years and over. (EV)